Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
A phase 3 trial testing Saruparib in prostate cancer, active and no longer recruiting.
Overview
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents is a phase 3 interventional study registered as NCT06120491, led by AstraZeneca, and active but no longer recruiting when checked on 2026-09-11. Official title: A Randomised, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01). Planned enrolment is 1898 participants (actual). The study started in 2023-11-21 and primary completion is expected in 2027-09-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Shares Saruparib, AstraZeneca, Prostate cancer and the tag ctgov-ingest.
- TrialA Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Shares AstraZeneca and the tag ctgov-ingest.
- TrialA Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Shares AstraZeneca and the tag ctgov-ingest.
- TrialAssessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Shares AstraZeneca and the tag ctgov-ingest.
- TrialAZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Shares AstraZeneca and the tag ctgov-ingest.
- TrialAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Shares AstraZeneca and the tag ctgov-ingest.
- TreatmentFPI-2265
Shares AstraZeneca, Prostate cancer and the tag ctgov-ingest.
- TreatmentAZD6621
Shares AstraZeneca, Prostate cancer and the tag ctgov-ingest.